11:20 AM EDT, 07/24/2024 (MT Newswires) -- Catalyst Pharmaceuticals ( CPRX ) said Wednesday it signed a license, supply, and commercialization agreement with Kye Pharmaceuticals, giving Kye exclusive rights to market AGAMREE (vamorolone), a treatment for Duchenne muscular dystrophy, in Canada.

As part of the deal, Kye will handle regulatory approval, marketing, and commercialization efforts in Canada, while Catalyst will supply the product and support Kye in securing approval from Health Canada, according to the company statement.

Catalyst said it will receive an upfront payment, with a potential for further reimbursement, sales milestones, and royalties for vamorolone.

Financial details were not disclosed.

Catalyst stock rose 1.3% in recent trading.

Price: 17.79, Change: +0.23, Percent Change: +1.31